These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 39151435)
1. The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study. Burgel PR; Sermet-Gaudelus I; Girodon E; Durieu I; Houdouin V; Audousset C; Macey J; Grenet D; Porzio M; Murris-Espin M; Reix P; Baravalle M; Belleguic C; Mely L; Verhille J; Weiss L; Reynaud-Gaubert M; Mittaine M; Hamidfar R; Ramel S; Cosson L; Douvry B; Danner-Boucher I; Foucaud P; Roy C; Burnet E; Raynal C; Audrezet MP; Da Silva J; Martin C; Lancet Respir Med; 2024 Aug; ():. PubMed ID: 39151434 [TBL] [Abstract][Full Text] [Related]
2. Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme. Dooney M; Saba T Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423592 [No Abstract] [Full Text] [Related]
3. Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme. Burgel PR Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423591 [No Abstract] [Full Text] [Related]
4. Compassionate Use of Lumacaftor/Ivacaftor in Cystic Fibrosis: Spanish Experience. Diab-Cáceres L; Girón-Moreno RM; Pastor-Sanz MT; Quintana-Gallego E; Delgado-Pecellín I; Blanco-Aparicio M; Maiz L; García-Clemente MM; Luna-Paredes C; Mondéjar-López P; Ruiz-de-Valbuena M; Fernández O; Barrio M; González M; López-Neyra A; Cols-I-Roig M; Palou-Rotger A; Gómez-de-Terreros-Caro FJ Arch Bronconeumol (Engl Ed); 2018 Dec; 54(12):614-618. PubMed ID: 30518496 [TBL] [Abstract][Full Text] [Related]
5. Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis. Odem-Davis K; Taylor-Cousar JL Lancet Respir Med; 2024 Aug; ():. PubMed ID: 39151435 [No Abstract] [Full Text] [Related]
8. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Smith S; Rowbotham NJ; Charbek E Cochrane Database Syst Rev; 2022 Aug; 8(8):CD008319. PubMed ID: 35914011 [TBL] [Abstract][Full Text] [Related]
9. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Ryan G; Jahnke N; Remmington T Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659 [TBL] [Abstract][Full Text] [Related]
10. Before It's Too Late: Multistakeholder Perspectives on Compassionate Access to Investigational Drugs for Pediatric Patients With Cancer. Gerasimov E; Donoghue M; Bilenker J; Watt T; Goodman N; Laetsch TW Am Soc Clin Oncol Educ Book; 2020 May; 40():1-10. PubMed ID: 32412804 [TBL] [Abstract][Full Text] [Related]
11. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Lo DK; Muhlebach MS; Smyth AR Cochrane Database Syst Rev; 2022 Dec; 12(12):CD009650. PubMed ID: 36511181 [TBL] [Abstract][Full Text] [Related]